The prognosis of Hodgkin’s disease is very good, with a good 5-year overall survival rate of 91% in patients under the age of 20. The modern treatment strategy for Hodgkin’s disease is based on chemotherapy combined with radiotherapy for large lymph node masses, and good results have been achieved. Radiotherapy can further improve the survival rate in poor prognosis type and reduce the side effects of treatment in good prognosis type. 1. Radiotherapy grouping criteria (1) Group 1: limited stage with good prognosis, stage IA/IIA, along with no serious other related indicators, histology of nodular sclerosis type and M/T ratio > 0.45, anemia (Hb < 10.5g/dl) or VS > 50. (2) Group 2: intermediate stage, stage IA/IIA, along with serious other related indicators, stage IB/IIB, stage IIE without Severe other related indicators, stage IIIA/IIIB without adjacent invasion. (3), Group 3: diffusion stage, stage IIIE, stage IV, with serious related indexes, stage IIE with large mediastinal M/T > 0.33 or invasion of at least 3 adjacent organs. 2. Radiotherapy regimen (1) Group 1: Treatment is initiated by 4 cycles of VBVP (vincristine, bleomycin, VP-16 and prednisone). If the lymph node mass responds to chemotherapy with a volume greater than 70%, 20 Gy is irradiated at the primary site of the tumor. 2 additional courses of OPPA chemotherapy (vincristine, procarbazine, prednisone and doxorubicin) are added. 2 courses of OPPA chemotherapy are followed by the dose of radiotherapy based on the response to chemotherapy (greater or less than 70%). With this treatment strategy, the vast majority of patients avoided the toxicity of the chemotherapy drugs given (about 85%). The overall survival rate was 97.5% and the disease-free survival rate was 91%. (2) Group 2: Chemotherapy consisted of 4 cycles of COPP/ABV crossover with vincristine, cyclophosphamide, procarbazine, doxorubicin, vincristine, bleomycin, and prednisone. If the lymph node mass responds to chemotherapy with a volume greater than 70%, irradiate 20 Gy at the primary site of the tumor. conversely add 2 courses of MINE chemotherapy regimen (promethazine, isocyclophosphamide, vincristine and VP-16). after 2 courses of chemotherapy, for good response, irradiate 20 Gy. for patients who do not respond the treatment plan should be discussed. (3) Group 3: chemotherapy consisting of 3 cycles of OPPA (vincristine, procarbazine, prednisone and doxorubicin) and 3 cycles of COPP (vincristine, cyclophosphamide, procarbazine and prednisone). Failure of this regimen is an indication for the use of second-line chemotherapy regimens and high-dose chemotherapy and blood stem cell transplantation. 3. Treatment of Hodgkin’s disease recurrence Hodgkin’s disease recurrence usually occurs 12 months after diagnosis, and the earlier the recurrence, the more serious it is. Recurrence of stage III or IV tumors is less likely to be cured because these patients have received intense radiotherapy and chemotherapy. Visceral tumor recurrence indicates disease progression. Recurrence at the site of tumor initiation and re-radiotherapy at a dose of at least 35Gy is required to achieve cure. All of these recurrences need to be treated intensively to have any hope of cure. However, these intensive treatments are often limited by the treatment already given and cannot be completed. Children with local recurrence of tumor may benefit from local radiotherapy.